Open Actively Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adults With APOL1- Mediated Proteinuric Kidney Disease

About

Brief Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 18 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 2/Phase 3

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
60 Years

Key Inclusion Criteria:

  • APOL1 genotype of G1/G1, G2/G2, or G1/G2
  • Proteinuric kidney disease

Key Exclusion Criteria:

  • Solid organ or bone marrow transplant
  • Uncontrolled hypertension
  • Diagnosis of diabetes mellitus
  • Known underlying cause of kidney disease including but not limited to sickle cell disease

Other protocol defined Inclusion/Exclusion criteria apply.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
22-000559
Category
Nephrology
Contact
Anita Mkrttchyan
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05312879
For detailed technical eligibility, visit ClinicalTrials.gov.